Overview

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

Status:
Completed

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
R-Pharm

Treatments:

Capecitabine